Abstract:P53 is well recognized to be a tumor suppressor protein. In response to the external stress or environmental perturbation, p53 can promote the transcription of various target genes downstream, thus regulating the cell cycle, apoptosis, DNA repair, and angiogenesis. However, the activation of p53 is further activated by another protein, MDM2, which negatively regulates the level of p53 inverse and thus reduces the activation of p53. This phenomenon is a novel potential and promising strategy for cancer therapy, i.e. restoring the activity of p53 pathway through the competitive inhibitors that can occupy the p53-binding site of MDM2 and thus inhibit the interaction between p53 and MDM2.Recently, various kinds of the inhibitors have been designed for this purpose. The Nutlin family is a group of well investigated inhibitors, which shows high efficiency for tumor suppression. Nutlin-3a mimics the MDM2-binding site of p53 essentially, and blocks the binding of MDM2 to p53. Once getting free from MDM2, p53 rapidly accumulates in the nuclei of cancer cells, the p53 target genes and the p53 pathway are activated, thereby resulting in cell-cycle arrest and apoptosis. In our previous papers, we investigated the competition mechanism between Nutlin3 and p53 in vitro by using molecular dynamics simulations. We found that Nutlin3 can bind faster than p53 to prevent p53 from binding to MDM2 when Nutlin-3a and p53 have equal distance from MDM2. Nutlin-3a can also bind to the p53-MDM2 complex to disturb and weaken the interactions between p53 and MDM2. However, the underlying mechanisms of p53-MDM2 complex instability in vivo are still unclear. And these inhibitors also have a variety of specificities and biological toxicities in vivo environment.In this study, we go a further step to investigate the effect of Nutlin-3a on the stability of p53-MDM2 complex in physiological environment with the aid of the molecular mechanics/generalized borne surface area (MM/GBSA) method. In our simulations, a group of Nutlin-3a molecules are randomly put around the p53 binding pocket of MDM2 in the initial stages to examine the dynamics among p53, MDM2 and the group of Nutlin-3a molecules and to analyze the underlying competition mechanism between Nutlin3 and p53 binding to pocket of MDM2.We find that Nutlin-3a can induce the centroid distance between p53 and MDM2 to increase. Importantly, we show that Nutlin-3a weakens the binding affinity of p53-MDM2 complex. Consistently, Nutlin-3a breaks a hydrogen bond between Phe19-Gln72 and a salt bridge between Glu17-Lys94, which weakens the interactions between p53 and MDM2. From the systematic biology point of view, the regulation of p53 by MDM2 is extremely sensitive to the strength of the p53-MDM2 interaction. The avianization of the interactions between p53 and MDM2 by Nutlin-3a can promote p53 to restore its suppression functions on tumor development.This study may be helpful in understanding the molecular mechanisms of p53-MDM2 complex instability mediated by Nutlin-3a and also in searching for the effective inhibitors of p53-MDM2 interaction.

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Persistent P21 Expression after Nutlin-3a Removal is Associated with Senescence-Like Arrest in 4n Cells

Modeling the Etiology of p53-mutated Cancer Cells

Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells

P53 and P21(waf1) Are Recruited to Distinct PML-Containing Nuclear Foci in Irradiated and Nutlin-3a-Treated U2OS Cells

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Two 4N Cell-Cycle Arrests Contribute to Cisplatin-Resistance.

Targeting P53 for Novel Anticancer Therapy.

P53 Dependent Centrosome Clustering Prevents Multipolar Mitosis in Tetraploid Cells

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

Current strategies to target p53 in cancer.

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

Tetraploid cells produced by absence of substrate adhesion during cytokinesis are limited in their proliferation and enter senescence after DNA replication

Restoration of p53 to limit tumor growth

P53-Dependent Autophagic Degradation of TET2 Modulates Cancer Therapeutic Resistance.

Effect of Nutlin-3a on Stability of P53-Mdm2 Complex

Interactions Between P53 And Mdm2 In A Mammalian-Cell Cycle Checkpoint Pathway